PATENT CLAIM ANALYSIS

Application Number: 16273878
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-08
Patent Classification: ["514", "255050"]

Abstract:
Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.

Claim (Index 46):
The method of  claim 41  wherein administration is by inhalation of single or multiple doses five times per day.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 99.0
- Lexical Diversity: 1.175
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14760139', '15660551', '15028347', '15796083', '11061386']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8606278025267129
- 35 USC 102 Novelty (BERT): 0.6003781256142632
- Combined Prediction Score: 0.8346028348354679
- Mean Citation Score: 479.36002400000007
- Max Citation Score: 669.2675
- Similarity Product: 348.3916733926535

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test